Literature DB >> 16389157

Colorectal cancer follow-up in 2005.

Thomas Anthony1.   

Abstract

The main goal in monitoring patients after the treatment of colorectal cancer is to improve survival through the early identification and treatment of metastatic or locally recurrent disease. Although the results of several randomized, controlled trials have identified a survival benefit associated with careful follow-up, specific testing strategies to maximize survival while minimizing cost and patient inconvenience have not been identified. There is, therefore, great variability in the types, number, and frequency of tests ordered to follow these patients. This article reviews the level-I data avail-able regarding the efficacy of follow-up, the specific tests commonly used, and issues of costs and patient satisfaction, and provides a summary of the available societal guidelines concerning colorectal cancer follow-up.

Entities:  

Mesh:

Year:  2006        PMID: 16389157     DOI: 10.1016/j.soc.2005.08.004

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  2 in total

1.  Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.

Authors:  Andrea L Small-Howard; Holden Harris
Journal:  J Immunoassay Immunochem       Date:  2010

Review 2.  Inflammatory bowel disease associated neoplasia: A surgeon's perspective.

Authors:  Azah A Althumairi; Mark G Lazarev; Susan L Gearhart
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.